Monopar Therapeutics (NASDAQ:MNPR) Now Covered by HC Wainwright

Key Points

• Monopar Therapeutics has received a "buy" rating from HC Wainwright, with a target price of $70.00, indicating a potential upside of 130.11% from its previous closing price.
• The company's stock has experienced significant volatility, with a fifty-two week range from $2.25 to $54.30, and a market capitalization of approximately $187.69 million.
• Insider trading activity included the sale of 42,504 shares by executives, which represents a reduction in their ownership stakes, highlighting potential concerns over insider confidence.

HC Wainwright assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $70.00 price target on the stock. HC Wainwright also issued estimates for Monopar Therapeutics' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.35) EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, August 13th. Finally, Cantor Fitzgerald began coverage on shares of Monopar Therapeutics in a research report on Monday, July 7th. They set an "overweight" rating and a $74.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $66.00.

Monopar Therapeutics Trading Down 5.3%

Shares of NASDAQ MNPR traded down $1.91 during mid-day trading on Tuesday, hitting $34.15. The company had a trading volume of 15,130 shares, compared to its average volume of 39,801. The company has a market capitalization of $210.71 million, a PE ratio of -10.26 and a beta of 1.05. The firm has a 50-day simple moving average of $37.87 and a two-hundred day simple moving average of $37.04. Monopar Therapeutics has a one year low of $2.25 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. Sell-side analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company's stock, valued at $206,920. The trade was a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares of the company's stock, valued at approximately $459,440. The trade was a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 over the last three months. Corporate insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. AlphaQuest LLC lifted its position in shares of Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company's stock valued at $64,000 after purchasing an additional 569 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Monopar Therapeutics during the second quarter valued at about $34,000. JPMorgan Chase & Co. lifted its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics during the second quarter valued at about $80,000. Finally, New York State Common Retirement Fund bought a new position in Monopar Therapeutics during the second quarter valued at about $104,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.